Two different approaches
ProcedurePlease refer to Groups
NCT Number: NCT05448690
The surgical treatment strategy for giant invasive pituitary adenoma is one of the current hot spots in the field of clinical research on pituitary adenoma. A comprehensive literature search resulted in numerous previous studies to investigate the efficacy, advantages and disadvantages of different surgical options.
A single approach (transnasal or craniotomy) is theoretically less invasive and has a shorter hospital stay for the patient, but may result in postoperative bleeding due to residual tumor and damage to the intracranial vessels adhering to the tumor.
The advantage of the combined approach is that the tumor can be removed to the greatest extent possible. In addition, postoperative suprasellar hemorrhage can be prevented by careful hemostasis or intracranial drainage by the transcranial team if necessary. In this way, the risk of postoperative bleeding due to residual tumor can be significantly reduced.
In some cases, waiting a few months after the initial surgery for a second-stage procedure may also be an option when the patient's condition does not allow for a combined access procedure, when the tumor is hard, or when the blood preparation is insufficient. However, staged surgery increases the financial burden on the patient, and local scar formation may make second-stage surgery more difficult and decrease the likelihood of endocrine remission of functional pituitary tumors.
Given the complexity of the treatment of giant invasive pituitary adenoma, there is a need to conduct studies comparing the combined transnasal cranial approach, the single access transnasal or cranial approach, and the staged approach simultaneously to assess whether the combined transnasal cranial approach is superior to the single access transnasal or cranial approach or the staged approach in improving the tumor resection rate in giant invasive pituitary adenoma.
Looking for future studies?
Notify Me6 year–85 year
All sexes
Interventional
Not applicable
Chongqing People's Hospital, Chongqing, Chongqing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Please refer to Groups
Either transnasal, transcranial or a staged approach
Time frame: One month after surgery
how much tumor was resected
Time frame: One month after surgery
Proportion of Participants with hemorrage, infection or cranial nerve defect
Time frame: From date of surgery until the date of first documented date of death from any cause, assessed up to 3 months after surgery
Death from any cause
Time frame: Three months after surgery
Ranged from 0 to 100, the higher scores mean a better outcome
Huashan Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07247526
Anxiety Disorders, Brain Diseases
Edirne, Turkey (Türkiye)
View Trial DetailsNCT03636568
Brain Diseases, Brain Neoplasms
St Louis, Missouri, United States
View Trial DetailsNCT01891838
Brain Diseases, Brain Neoplasms
Suresnes, France
View Trial DetailsNCT05320718
Anesthesia, Local, Regional Anesthesia
Beijing, Beijing Municipality, China
View Trial Details